News
CLYM
11.66
-1.93%
-0.23
Climb Bio added to ‘Analysts Current Favorites’ at Raymond James
TipRanks · 2d ago
Weekly Report: what happened at CLYM last week (0914-0918)?
Weekly Report · 4d ago
10 small-cap healthcare stocks with the strongest momentum grades
Seeking Alpha · 09/17 14:20
Small-cap stocks with strong momentum grades and triple-digit YTD gains
Seeking Alpha · 09/17 13:55
Weekly Report: what happened at CLYM last week (0907-0911)?
Weekly Report · 09/14 09:45
Climb Bio Is Maintained at Outperform by Oppenheimer
Dow Jones · 09/08 17:05
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
Benzinga · 09/08 16:55
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 09/08 13:07
Climb Bio Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 09/08 11:31
Climb Bio Price Target Raised to $30.00/Share From $24.00 by HC Wainwright & Co.
Dow Jones · 09/08 11:31
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30
Benzinga · 09/08 11:21
Climb Bio price target raised to $30 from $24 at H.C. Wainwright
TipRanks · 09/08 10:15
Weekly Report: what happened at CLYM last week (0831-0904)?
Weekly Report · 09/07 09:41
Noteworthy Friday Option Activity: TYRA, CLYM, AVBP
NASDAQ · 09/04 19:50
Climb Bio Price Target Raised to $30.00/Share From $26.00 by B. Riley Securities
Dow Jones · 09/04 17:52
B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30
Benzinga · 09/04 17:42
Analysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (PMVP) and Climb Bio (CLYM)
TipRanks · 09/04 12:50
Climb Bio price target raised to $30 from $26 at B. Riley
TipRanks · 09/04 12:26
Jade Biosciences price target raised to $48 from $25 at Clear Street
TipRanks · 09/03 20:16
Climb Bio Is Maintained at Buy by BTIG
Dow Jones · 09/03 18:24
More
Webull provides a variety of real-time CLYM stock news. You can receive the latest news about Climb Bio through multiple platforms. This information may help you make smarter investment decisions.
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.